Preparation of monoclonal antibodies for detection of recombinant flagellin C from Pseudomonas Aeruginosa

Cover Page

Cite item

Full Text

Abstract

An important virulence factor in the pathogenesis of infections caused by Pseudomonas aeruginosa is flagellin: it serves as the main structural component of the bacterial flagellum and an acceptor for the TLR5 receptor of the innate immune system. Toll-like receptor 5 is able to bind bacterial flagellin and activate the anti-inflammatory transcription factor NF-kB through the adapter protein MyD88, which induces the production of anti-inflammatory cytokines. The inclusion of flagellin in recombinant proteins increased the ability to stimulate the production of anti-inflammatory cytokines and activate antigen-presenting cells. A number of experiments have shown that the use of flagellin as a molecular adjuvant in vaccines increases the expression of CD80, CD83, CD86 and MHC II molecules on the surface of dendritic cells, and also leads to an increase in the secretion of IFNγ and α-defensins by dendritic and NK cells; T cell proliferation and activation of antigen-specific cytotoxic T lymphocytes, as well as increased induction of antigen-specific IgG and IgA antibodies. Due to the natural and acquired resistance of P. aeruginosa to antibiotics, the available choice of antipseudomonas drugs is decreasing, and therefore the problem of developing effective therapeutic drugs to protect against this infection is of high medical and social importance. For this purpose, it seems promising to study the immunobiological properties of P. aeruginosa flagellin as a possible vaccine component. Based on this, in the Laboratory of Protective Antigens of the I. Mechnikov Research Institute of Vaccines and Sera, recombinant flagellin C (FliC) of P. aeruginosa was obtained, and its immunogenicity and protective properties were proven. However, the question of standardizing methods for screening and monitoring the resulting recombinant FliC protein remains open. To solve this issue, hybridomas producing monoclonal antibodies (mAb) of a given specificity were obtained, the basic immunochemical properties of mAbs were studied, and the possibility of using them as reagents in constructing a test system for identifying and standardizing the recombinant FliC protein upon its production was assessed. Purpose of the work: to obtain monoclonal antibodies to the recombinant flagellin C protein of P. aeruginosa; to study their basic immunochemical properties and to evaluate the possibility of using the recombinant FliC protein for screening and control.

About the authors

Anton P. Zherebtsov

I. Mechnikov Research Institute of Vaccines and Sera

Author for correspondence.
Email: antonzherebtsov@yandex.ru

Researcher, Laboratory of the Protective Antigens

Russian Federation, 105064, Moscow, Maly Kazenny lane, 5a

I. V. Yakovleva

I. Mechnikov Research Institute of Vaccines and Sera

Email: antonzherebtsov@yandex.ru

PhD (Biology), Leading Researcher, Laboratory of Therapeutic Vaccines

Russian Federation, 105064, Moscow, Maly Kazenny lane, 5a

N. F. Gavrilova

I. Mechnikov Research Institute of Vaccines and Sera

Email: antonzherebtsov@yandex.ru

PhD (Biology), Senior Researcher, Laboratory of Therapeutic Vaccines

Russian Federation, 105064, Moscow, Maly Kazenny lane, 5a

N. A. Mikhailova

I. Mechnikov Research Institute of Vaccines and Sera

Email: antonzherebtsov@yandex.ru

DSc (Medicine), Professor, Head of the Laboratory of the Protective Antigens

Russian Federation, 105064, Moscow, Maly Kazenny lane, 5a

References

  1. Бурчанов Ю.И. Моноклональные антитела: от создания до клинического применения // Клиническая онкогемато логия, фундаментальные исследования и клиническая практика. 2016. Т. 9, № 3. С. 237–244. [Burchanov Yu.I. Monoclonal antibodies: from creation to clinical use. Klinicheskaya onkogematologiya, fundamental’nye issledovaniya i klinicheskaya praktika = Clinical Oncohematology, Fundamental Research and Clinical Practice, 2016, vol. 9, no. 3, pp. 237–244. (In Russ.)] doi: 10.21320/2500-2139-2016-9-3-237-244
  2. Волкова Н.П. Физико-химические свойства белков и методы их выделения / Биохимия: учебник; под ред. Е.С. Северина. 5-е изд., испр. и доп. М.: ГЭОТАР-Медиа, 2019. С. 66–72. [Volkova N.P. Physico-chemical properties of proteins and methods of their isolation. In: Biochemistry: textbook. 5th ed. Moscow: GEOTAR-Media, 2019, pp. 66–72. (In Russ.)]
  3. Духовлинов И.В., Богомолова Е.Г., Федорова Е.А., Симбирцев А.С. Исследование протективной активности кандидатной вакцины против ротавирусной инфекции на основе рекомбинантного белка FliCVP6VP8 // Медицинская иммунология. 2016. Т. 18, № 5. С. 417–424. [Dukhovlinov I.V., Bogomolova E.G., Fedorova E.A., Simbirtsev A.S. Protective activity study of a candidate vaccine against rotavirus infection based on recombinant protein FliCVP6VP8. Meditsinskaya Immunologiya = Medical Immunology (Russia), 2016, vol. 18, no. 5, pp. 417–424. (In Russ.)] doi: 10.15789/1563-0625-2016-5-417-424
  4. Жеребцов А.П., Калошин А.А., Михайлова Н.А. Получение рекомбинантного флагеллина C Pseudomonas aeruginosa и изучение его иммунобиологических свойств // БИОпрепараты. Профилактика, диагностика, лечение. 2024. Т. 24, № 1. С. 91–102. [Zherebtsov A.P., Kaloshin A.A., Mikhailova N.A. Production and immunological characterisation of recombinant flagellin C of Pseudomonas aeruginosa. Biopreparaty. Profilaktika, diagnostika, lechenie = Biopreparations. Prevention, Diagnosis, Treatment, 2024, vol. 24, no. 1, pp. 91–102. (In Russ.)] doi: 10.30895/2221-996X-2024-24-1-91-102
  5. Патент № 2793753 Российская Федерация, МПК C12N 1/21 (2006.01), C12N 15/31 (2006.01), C12N 15/70 (2006.01). Рекомбинантная плазмидная ДНК pPA-FlicC, кодирующая синтез рекомбинантного флагеллина-С Pseudomonas aeruginosa, штамм Escherichia coli PA-FlicC — продуцент гибридного рекомбинантного белка и способ получения указанного белка: № 2022123813; заявлено 07.09.2022: опубликовано 05.04.2023 / Калошин А.А., Жеребцов А.П., Михайлова Н.А. Патентообладатель: ФГБНУ НИИВС им. И.И. Мечникова. 18 с. [Patent No. 2793753 Russian Federation, Int. Cl. C12N 1/21 (2006.01), C12N 15/31 (2006.01), C12N 15/70 (2006.01). Recombinant plasmid DNA pPA-FlicCencoding synthesis ofrecombinant flagellinc pseudomonas aeruginosa, strain Escherichia coli PA-FlicC — producer of the hybrid recombinant protein and a method for producing said protein. No. 2022123813; application: 07.09.2022: date of publication 05.04.2023 / Kaloshin A.A., Zherebtsov A.P., Mikhailova N.A. Proprietors: Federalnoe gosudarstvennoe byudzhetnoe nauchnoe uchrezhdenie «Nauchno-issledovatelskij institut vaktsin i syvorotok im. I.I. Mechnikova» (FGBNU NIIVS im. I.I. Mechnikova). 18 p.]
  6. Софронов Г.А., Мурзина Е.В., Болехан В.Н., Веселова О.М., Симбирцев А.С. Перспективные направления использования препаратов на основе рекомбинантного флагеллина // Медицинский академический журнал. 2017. Т. 17, № 2. C. 7–20. [Sofronov G.A., Murzina E.V., Bolekhan V.N., Veselova O.M., Simbirtsev A.S. Perspective direction of using flagellin based drugs. Meditsinskii akademicheskii zhurnal = Medical Academic Journal, 2017, vol. 17, no. 2, pp. 7–20. (In Russ.)] doi: 10.17816/MAJ1727-20
  7. Barnea Y., Carmeli Y., Neville L.F., Kahel-Reifer H., Eren R., Dagan S., Navon-Venezia S. Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model. Burns, 2009, vol. 35, no. 3, pp. 390–396. doi: 10.1016/j.burns.2008.08.014
  8. Chiang H.-Y., Chen T.-C., Lin C.-C., Ho L.-C., Kuo C.-C., Chi C.-Y. Trend and predictors of short-term mortality of adult bacteremia at emergency departments: a 14-year cohort study of 14625 patients. Open Forum Infect. Dis., 2021, vol. 8, no. 11: ofab485. doi: 10.1093/ofid/ofab485
  9. Cui B., Liu X., Fang Y., Zhou P., Zhang Y., Wang Y. Flagellin as a vaccine adjuvant. Expert Rev. Vaccines, 2018, vol. 17, no. 4, pp. 335–349. doi: 10.10⁸0/14760584.2018.1457443
  10. Felgner S., Spöring I. The immunogenic potential of bacterial flagella for Salmonella-mediated tumor therapy. Int. J. Cancer, 2020, vol. 147, no. 2, pp. 448–460. doi: 10.1002/ijc.32807
  11. Hajam I.A., Dar P.A., Shahnawaz I., Jaume J.C., Lee J.H. Bacterial flagellin-a potent immunomodulatory agent. Exp. Mol. Med., 2017, vol. 49, no. 9: e373. doi: 10.1038/emm.2017.172
  12. Laemmli U.K. Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature, 1970, vol. 227, pp. 680–685. doi: 10.1038/227680a0
  13. Spagnolo A.M., Sartini M., Cristina M.L. Pseudomonas aeruginosa in the healthcare facility setting. Rev. Med. Microbiol., 2021, vol. 32, no. 3, pp. 169–175. doi: 10.1097/MRM.0000000000000271

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure 1. Study of the specificity of the obtained mAbs in immunoblotting

Download (291KB)
3. Figure 2. Determination of the epitope targeting of the obtained mAbs

Download (401KB)

Copyright (c) 2024 Zherebtsov A.P., Yakovleva I.V., Gavrilova N.F., Mikhailova N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies